Holen Sie sich die Stockscreener-App
216.26
0.62%
-1.35
Handel nachbörslich:
216.25
-0.010
-0.00%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ABBV?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$217.61
Offen:
$218.33
24-Stunden-Volumen:
4.25M
Relative Volume:
0.78
Marktkapitalisierung:
$382.04B
Einnahmen:
$58.33B
Nettoeinkommen (Verlust:
$3.73B
KGV:
102.98
EPS:
2.1
Netto-Cashflow:
$18.24B
1W Leistung:
+2.78%
1M Leistung:
+4.63%
6M Leistung:
+2.12%
1J Leistung:
+10.49%
1-Tages-Spanne:
$215.84
$218.71
1-Wochen-Bereich:
$208.44
$221.76
52-Wochen-Spanne:
$163.81
$221.76
Abbvie Inc Stock (ABBV) Company Profile
Firmenname
Abbvie Inc
Sektor
Telefon
(847) 932-7900
Adresse
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Vergleichen Sie ABBV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
216.26 | 384.42B | 58.33B | 3.73B | 18.24B | 2.10 |
|
LLY
Lilly Eli Co
|
764.71 | 670.72B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
176.46 | 427.24B | 90.62B | 22.66B | 18.18B | 9.35 |
|
NVS
Novartis Ag Adr
|
122.78 | 238.71B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
81.09 | 202.37B | 63.43B | 16.42B | 14.72B | 6.49 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-12 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-05 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-04 | Hochstufung | Argus | Hold → Buy |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-06-05 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-05-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-01-29 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-12-11 | Hochstufung | Goldman | Neutral → Buy |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-30 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-07-25 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-05 | Herabstufung | Argus | Buy → Hold |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2023-02-22 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | Hochstufung | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-11-08 | Herabstufung | Societe Generale | Buy → Hold |
| 2022-08-01 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Underperform |
| 2022-05-06 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-02-28 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-03 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-03 | Bestätigt | Barclays | Equal Weight |
| 2022-02-03 | Bestätigt | BofA Securities | Neutral |
| 2022-02-03 | Bestätigt | Goldman | Neutral |
| 2022-01-13 | Eingeleitet | Redburn | Buy |
| 2022-01-12 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-11-23 | Hochstufung | Societe Generale | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Outperform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-23 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | Hochstufung | Argus | Hold → Buy |
| 2020-05-18 | Fortgesetzt | BofA/Merrill | Neutral |
| 2020-05-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-05-11 | Fortgesetzt | Morgan Stanley | Overweight |
| 2020-04-20 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | Bestätigt | Cowen | Outperform |
| 2019-09-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-08-20 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | Eingeleitet | Goldman | Neutral |
| 2019-04-29 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
Alle ansehen
Abbvie Inc Aktie (ABBV) Neueste Nachrichten
September 16, 2025 - Pharmaceutical Executive
AbbVie: Best Time To Sell In 5 Years (Rating Downgrade) (NYSE:ABBV) - Seeking Alpha
Guggenheim Reiterates a Buy Rating on AbbVie (ABBV), Sets a PT of $227 - Yahoo Finance
Is ABBV Stock a Buy, Hold, or Sell After Its Almost 23% Rise YTD? - sharewise.com
AbbVie (ABBV)’s Dividend Track Record: How It Became a Leader in Consistent Dividends - Yahoo Finance
With big pharma circling psychedelics, the next breakthrough may not come from tripping at all - microdose.buzz
JPMorgan Adjusts Price Target on AbbVie to $235 From $200, Maintains Overweight Rating - MarketScreener
AbbVie Settles Rinvoq Litigation, Blocks Generics Until 2037 - Law360
AbbVie's VRAYLAR® Gains Public Reimbursement In Alberta For Schizophrenia Treatment - Nasdaq
AbbVie loses appeal over Mississippi 340B state law - Endpoints News
11 Newly Overvalued Stocks for the Week - Morningstar
AbbVie Says Vraylar Antipsychotic Medication Now Listed on Alberta's Health Drug Formulary - MarketScreener
Deutsche Bank Adjusts Price Target on AbbVie to $204 From $173 - MarketScreener
AbbVie's VRAYLAR®? (Cariprazine) Now Publicly Reimbursed in Alberta - MarketScreener
Cantor Fitzgerald Adjusts AbbVie Price Target to $245 From $215, Maintains Overweight Rating - MarketScreener
Deutsche Bank Adjusts AbbVie Price Target to $204 From $173, Maintains Hold Rating - MarketScreener
AbbVie loses bid to block 340B law in Mississippi - pharmaphorum
What would a sea change in drug advertising mean for big-spending AbbVie? - Crain's Chicago Business
Barrett's Esophagus Strategic Business Report 2025-2030 Featuring 34 Companies - GlobeNewswire Inc.
Capital Market Strategies LLC Sells 1,975 Shares of AbbVie Inc. $ABBV - MarketBeat
Teamwork Financial Advisors LLC Has $595,000 Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Bought by First Financial Bank Trust Division - MarketBeat
AbbVie Inc. $ABBV Shares Purchased by Wesbanco Bank Inc. - MarketBeat
LVM Capital Management Ltd. MI Has $31.06 Million Holdings in AbbVie Inc. $ABBV - MarketBeat
Jacobs & Co. CA Buys 1,211 Shares of AbbVie Inc. $ABBV - MarketBeat
Good Steward Wealth Advisors LLC Sells 1,932 Shares of AbbVie Inc. $ABBV - MarketBeat
Neville Rodie & Shaw Inc. Trims Stake in AbbVie Inc. $ABBV - MarketBeat
Park National Corp OH Has $21.83 Million Stake in AbbVie Inc. $ABBV - MarketBeat
Belpointe Asset Management LLC Sells 4,903 Shares of AbbVie Inc. $ABBV - MarketBeat
Intech Investment Management LLC Sells 90,154 Shares of AbbVie Inc. $ABBV - MarketBeat
Dynamic Technology Lab Private Ltd Invests $383,000 in AbbVie Inc. $ABBV - MarketBeat
Acadian Asset Management LLC Acquires 7,640 Shares of AbbVie Inc. $ABBV - MarketBeat
Fortis Capital Advisors LLC Has $993,000 Stock Position in AbbVie Inc. $ABBV - MarketBeat
Blue Rock Wealth Management LLC Buys New Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Acquired by Thurston Springer Miller Herd & Titak Inc. - MarketBeat
TruWealth Advisors LLC Has $26.46 Million Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
McAdam LLC Reduces Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
Ransom Advisory Ltd Acquires Shares of 13,215 AbbVie Inc. $ABBV - MarketBeat
Integrity Alliance LLC. Purchases 20,680 Shares of AbbVie Inc. $ABBV - MarketBeat
IFM Investors Pty Ltd Purchases 3,741 Shares of AbbVie Inc. $ABBV - MarketBeat
Glenview Trust co Boosts Holdings in AbbVie Inc. $ABBV - MarketBeat
Anchor Investment Management LLC Reduces Stake in AbbVie Inc. $ABBV - MarketBeat
Focus Partners Wealth Has $112.77 Million Stock Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie (NYSE:ABBV) Price Target Raised to $260.00 at Wells Fargo & Company - MarketBeat
AbbVie (NYSE:ABBV) Given New $240.00 Price Target at BMO Capital Markets - MarketBeat
AbbVie (ABBV) Receives a Buy from Guggenheim - The Globe and Mail
William Blair Forecasts AbbVie's FY2027 Earnings (NYSE:ABBV) - MarketBeat
Guinness Asset Management LTD Trims Stock Position in AbbVie Inc. $ABBV - MarketBeat
Swedbank AB Lowers Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
Voya Investment Management LLC Has $544.72 Million Stock Position in AbbVie Inc. $ABBV - MarketBeat
AG2R LA Mondiale Gestion D Actifs Acquires New Shares in AbbVie Inc. $ABBV - MarketBeat
Finanzdaten der Abbvie Inc-Aktie (ABBV)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.53%
0.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):